Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups
The benefits of SGLT2 inhibitors are seen in patients with heart failure and in those with chronic kidney disease, data from two pivotal trials, EMPEROR-Reduced and DAPA-CKD, show.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Chronic Kidney Disease | Diabetes | Endocrinology | Health | Heart | Heart Failure | SGLT2 Inhibitors | Urology & Nephrology